Literature DB >> 27832457

Pulmonary Arterial Hypertension and the Sex Hormone Paradox.

Andrew Foderaro1,2, Corey E Ventetuolo3,4,5.   

Abstract

PURPOSE OF REVIEW: Prevalence and outcome differences between women and men with pulmonary arterial hypertension (PAH) raise questions about the role of sex hormones in disease pathobiology. This review will summarize the current understanding of sex and sex hormone pathways and their influence on heart-lung function in health and in disease. RECENT
FINDINGS: Female sex has been shown to be a risk factor for the development of PAH, but women have improved survival compared to men with PAH. These paradoxical observations are likely driven in part by complex sex hormone signaling and processing pathways and their interaction with the pulmonary vasculature and the right ventricle. These relationships may vary depending on an individual's underlying sex, age, and/or genetic substrate. The study of the connections between sex, sex hormones, the pulmonary circulation, and the right ventricle may improve our understanding of disease epidemiology and outcomes and lead to new treatment strategies for PAH.

Entities:  

Keywords:  Estrogen paradox; Pulmonary hypertension; Right ventricle; Sex hormones

Mesh:

Substances:

Year:  2016        PMID: 27832457     DOI: 10.1007/s11906-016-0689-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  67 in total

1.  Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension.

Authors:  Garvan C Kane; Hilal Maradit-Kremers; Josh P Slusser; Chris G Scott; Robert P Frantz; Michael D McGoon
Journal:  Chest       Date:  2010-11-11       Impact factor: 9.410

2.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.

Authors:  Serge A van Wolferen; Johannes T Marcus; Anco Boonstra; Koen M J Marques; Jean G F Bronzwaer; Marieke D Spreeuwenberg; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

3.  Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Authors:  Kirsty M Mair; Audrey F Wright; Nicholas Duggan; David J Rowlands; Martin J Hussey; Sonia Roberts; Josephine Fullerton; Margaret Nilsen; Lynn Loughlin; Matthew Thomas; Margaret R MacLean
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

4.  Sex differences in response to tadalafil in pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Paul M Hassoun; Milo A Puhan; Yi Zhou; Robert A Wise
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

5.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.

Authors:  Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  J Am Coll Cardiol       Date:  2011-12-06       Impact factor: 24.094

6.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Authors:  E D Austin; J D Cogan; J D West; L K Hedges; R Hamid; E P Dawson; L A Wheeler; F F Parl; J E Loyd; J A Phillips
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

7.  Determinants of right ventricular ejection fraction in pulmonary arterial hypertension.

Authors:  Steven M Kawut; Nadine Al-Naamani; Cara Agerstrand; Erika Berman Rosenzweig; Cherise Rowan; Robyn J Barst; Steven Bergmann; Evelyn M Horn
Journal:  Chest       Date:  2008-10-10       Impact factor: 9.410

8.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

Review 9.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

10.  Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Authors:  Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean
Journal:  Circulation       Date:  2012-08-02       Impact factor: 29.690

View more
  19 in total

1.  Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research.

Authors:  Tim Lahm; Steven M Kawut
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  The Y Chromosome Takes the Field to Modify BMPR2 Expression.

Authors:  Andrea L Frump; Tim Lahm
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

3.  Sex and Gender Differences in Lung Disease.

Authors:  Patricia Silveyra; Nathalie Fuentes; Daniel Enrique Rodriguez Bauza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Y Not? Sex Chromosomes May Modify Sexual Dimorphism in Pulmonary Hypertension.

Authors:  Eric D Austin; Rizwan Hamid
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

5.  DHT deteriorates the progression of monocrotaline-induced pulmonary arterial hypertension: effects of endogenous and exogenous androgen.

Authors:  Juan Wen; Jiajie Wang; Xiaohong Tang; Shangbin Deng; Jia Dai; Xiaohui Li; Weijun Cai
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

6.  Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Authors:  Matthew Austin; Peter J Quesenberry; Corey E Ventetuolo; Olin Liang; John L Reagan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-05-13

Review 7.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

8.  Roles of Genetic Predisposition in the Sex Bias of Pulmonary Pathophysiology, as a Function of Estrogens : Sex Matters in the Prevalence of Lung Diseases.

Authors:  An Huang; Sharath Kandhi; Dong Sun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Exogenous Estrogen Preserves Distal Pulmonary Arterial Mechanics and Prevents Pulmonary Hypertension in Rats.

Authors:  Jennifer L Philip; Diana M Tabima; Gregory D Wolf; Andrea L Frump; Tik-Chee Cheng; David A Schreier; Timothy A Hacker; Tim Lahm; Naomi C Chesler
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 30.528

10.  Lumped-parameter models of the pulmonary vasculature during the progression of pulmonary arterial hypertension.

Authors:  Jesse W Gerringer; Julie C Wagner; Daniela Vélez-Rendón; Daniela Valdez-Jasso
Journal:  Physiol Rep       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.